REVA Medical, LLC

REVA Medical is a leader in bioresorbable polymer technologies for vascular interventional applications. The company develops and commercializes implantable medical devices using proprietary bioresorbable polymer platforms, specifically Tyrocore™, designed to support vascular healing and then safely resorb from the body. Primary product focus is on peripheral vascular interventions. MOTIV is a bioresorbable scaffold approved by CE Mark for below-the-knee (BTK) peripheral artery disease treatment and has received FDA Breakthrough Technology Designation in the United States. The company also manufactures Fantom Encore, a third-generation bioresorbable scaffold featuring radiopacity, thin struts, and simplified deployment characteristics. TyroSphere represents expansion into embolic microsphere technology for hypervascular tumor treatment, offering both bioresorbable resorption and radiopacity for imaging guidance. Tyrocore™ is REVA's proprietary polymer platform invented specifically for implantable bioresorbable devices. The company's devices are positioned for interventional radiology and vascular surgery markets, with clinical validation through controlled trials including MOTIV BTK trials and FANTOM II 5-year outcome studies. Manufacturing and regulatory capabilities span CE Mark approval pathways and FDA breakthrough designation processes.